Howard G. Welgus, a director of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), filed a Form 4 on August 19, 2026, disclosing stock option exercises and a sale of common stock on August 17, 2026, executed under a pre-established 10b5-1 trading plan.

Key Highlights

  • Shares sold: Welgus disposed of 4,730 shares of common stock at a weighted average price of $26.1807, with individual transactions ranging from $26.10 to $26.25.
  • Options exercised: Three separate stock option tranches were exercised: 822 shares at $6.5223, 1,019 shares at $7.51, and 2,255 shares at $8.63, all on August 17, 2026.
  • Post-transaction ownership: Following all reported transactions, Welgus directly beneficially owned 36,475 shares of common stock.
  • 10b5-1 plan: All transactions were made pursuant to a 10b5-1 trading plan adopted on March 13, 2026, with a plan end date of June 15, 2027.
  • Options fully vested: According to the filing, all three exercised stock options were fully vested at the time of exercise.
  • Remaining derivative holdings: After the exercises, Welgus retained 7,396, 9,163, and 20,287 options under the three respective stock option grants, per the filing.

Welgus Option Exercises and Share Sale Details for Arcutis Biotherapeutics

According to the filing, Howard G. Welgus, identified as a director of Arcutis Biotherapeutics, Inc., reported three "M" (exercise of derivative security) transactions and one "S" (sale) transaction on August 17, 2026. The three option exercises covered shares with exercise prices of $6.5223, $7.51, and $8.63, corresponding to options expiring on November 20, 2029, May 31, 2033, and June 14, 2034, respectively. The filing states that the price of each derivative security at exercise was $0.

The subsequent sale of 4,730 shares of common stock was reported at a weighted average price of $26.1807. The filing notes that "the shares were sold in multiple transactions at prices ranging from $26.10 to $26.25 inclusive," and that full information on shares sold at each price within that range is available upon request to the SEC staff, the issuer, or a security holder. After all transactions, the filing reports Welgus directly held 36,475 shares of common stock.

The filing was signed on August 19, 2026, by Latha Vairavan as Attorney-in-Fact for Howard G. Welgus. The filing also indicates that a box was checked confirming the transactions were made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), with the plan having been adopted on March 13, 2026.

What Was Disclosed

The Form 4 discloses that director Howard G. Welgus of Arcutis Biotherapeutics exercised three fully vested stock options and sold 4,730 shares of common stock on August 17, 2026, under a 10b5-1 plan, leaving him with 36,475 directly held shares.